Tag: Lebrikizumab

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Lebrikizumab

Almirall's solid core business Q1 performance boosted by Growth drivers momentum

Added to Collection on: 2021-05-10 05:37:30

Tags for this article:

Life Sciences
Profit
Biotechnology
Health sciences
Almirall
Monoclonal antibodies
Psoriasis
Lebrikizumab
Earnings before interest, taxes, depreciation, and amortization
Financial ratio
Net income
Biopharmaceutical
Almirall S.A.

Click the tags to see associated articles and topics

View Article Details
Almirall delivers robust H1 performance and increases full-year guidance

Added to Collection on: 2021-07-26 05:15:00

Tags for this article:

Companies
Health care
Medical specialties
Profit
Almirall
Ethers
Monoclonal antibodies
Tirbanibulin
Lebrikizumab
Psoriasis
Earnings before interest, taxes, depreciation, and amortization
AstraZeneca
Efinaconazole
France
Almirall S.A.

Click the tags to see associated articles and topics

View Article Details
Lilly's lebrikizumab looks to outdo Dupixent

Added to Collection on: 2021-08-02 14:03:45

Tags for this article:

Monoclonal antibodies
Drugs
Health care
Health sciences
Breakthrough therapy
Dupilumab
Sanofi
EASI
Dermatitis
Janus kinase inhibitor
Regeneron Pharmaceuticals
Lebrikizumab

Click the tags to see associated articles and topics

View Article Details
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to ...

Added to Collection on: 2021-08-16 08:14:59

Tags for this article:

Medical specialties
Medicine
Clinical medicine
Type I hypersensitivity
Monoclonal antibodies
Lebrikizumab
Autoimmune diseases
Eli Lilly and Company
Type 2 inflammation
Atopic dermatitis
Dermatitis
Atopy

Click the tags to see associated articles and topics

View Article Details
Lilly's new eczema drug scores in late-stage studies | BioPharma Dive

Added to Collection on: 2021-08-16 16:18:45

Tags for this article:

Health sciences
Health care
Health
Monoclonal antibodies
Autoimmune diseases
Sanofi
CAC 40
Regeneron Pharmaceuticals
Lebrikizumab
Pharmaceutical industry
Dupilumab
Eli Lilly

Click the tags to see associated articles and topics

View Article Details
Leo Pharma's FDA nod adds a challenger to Dupixent's dominance in eczema - MedCity News

Added to Collection on: 2021-12-28 17:18:49

Tags for this article:

Health sciences
Life Sciences
Health care
Monoclonal antibodies
Type I hypersensitivity
Tralokinumab
Dupilumab
Atopic dermatitis
Dermatitis
Regeneron Pharmaceuticals
Sanofi
Lebrikizumab
United States
Leo Pharma

Click the tags to see associated articles and topics

View Article Details
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal ...

Added to Collection on: 2022-03-26 22:45:04

Tags for this article:

Medical specialties
Immunology
Clinical medicine
Type I hypersensitivity
Monoclonal antibodies
Lebrikizumab
Autoimmune diseases
Type 2 inflammation
Eli Lilly and Company
EASI
Atopic dermatitis
Eczema Area and Severity Index
New York

Click the tags to see associated articles and topics

View Article Details
Lilly Poised to Take on Competitors in Atopic Dermatitis | BioSpace

Added to Collection on: 2022-04-12 19:23:04

Tags for this article:

Medical specialties
Monoclonal antibodies
Immunology
Type I hypersensitivity
Organ systems
Corticosteroids
Breakthrough therapy
Dupilumab
Sanofi
Lebrikizumab
Atopic dermatitis
Dermatitis
Eli Lilly

Click the tags to see associated articles and topics

View Article Details
Managing Atopic Dermatitis with Lebrikizumab | CCID - Dove Medical Press

Added to Collection on: 2022-06-07 13:55:25

Tags for this article:

Monoclonal antibodies
Medical specialties
Organ systems
Immunology
Lebrikizumab
Dupilumab
Atopic dermatitis
Upadacitinib
Immunoglobulin E
Idiopathic pulmonary fibrosis
Dermatitis
Tralokinumab

Click the tags to see associated articles and topics

View Article Details